Tocomin® SupraBio Supports Liver Health

EDISON, N.J.Preliminary results from an ongoing clinical trial on tocotrienols suggest the compounds may help treat non-alcoholic fatty liver disease (NAFLD). The clinical trial is evaluating the neuroprotective and anti-atherogenic properties of Tocomin® SupraBio, a patented, bioenhanced full-spectrum palm tocotrienol complex. Secondary objectives of the human study include evaluating the effects of tocotrienols on blood parameters including lipid profile, Apo-B, C-reactive protein (CRP), fatty liver accumulation, antioxidant profile, Lp(a) and lipid peroxidation.

The researchers looking at the secondary endpoint about fatty liver accumulation found taking Tocovid SupraBio 200 mg twice daily was significantly effective in treating NAFLD, according to Carotech, the supplier of Tocomin. Two-thirds (66.7 percent) of the supplemented subjects (n=30) showed significant improvement in their fatty liver condition; 15 patients were completed cured after one year of treatment. This research work has been accepted for presentation at the Liver Meeting of the American Association for the Study of Liver Diseases (ASSLD) to be held in Boston.